Clinical Trials

Status
Published

1525 Results

Open
Phase
III
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial

Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2021
ClinicalTrials.gov Registry Number
NCT04637594
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2021
ClinicalTrials.gov Registry Number
NCT04216290
Open
Phase
II
Accrual
4%
SWOG Clinical Trial Number
S1900E

A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Status Notes
S1900E will open to accrual April 2, 2021, effective 12:00 pm PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
04-02-2021
Open
Phase
II-III
Accrual
0%
SWOG Clinical Trial Number
S1918

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

Status Notes
Activation - Effective 3/19/21, 12:00 pm Pacific Time

Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.

Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.

Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Research Committee(s)
Lymphoma
Activated
03-19-2021
ClinicalTrials.gov Registry Number
04799275
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S1937

A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.

Status Notes
This study is open to accrual effective February 16, 2021.
Research Committee(s)
Genitourinary Cancer
Activated
02-16-2021
ClinicalTrials.gov Registry Number
NCT04579224
Open
Phase
III
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

Status Notes
Activation - Effective 12/15/20, 12:00 PM Pacific Time

All protocol documents will be accessible from the S2007 protocol abstract page on www.ctsu.org after activation on 12/15/20 (login required).
Research Committee(s)
Breast Cancer
Activated
12-15-2020
ClinicalTrials.gov Registry Number
04647916
Open
Accrual
1%
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

Status Notes
Active effective 12/14/20
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12-14-2020
ClinicalTrials.gov Registry Number
04269902
Open
Phase
II
Accrual
1%
SWOG Clinical Trial Number
S2001

Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects

Status Notes
Activation, Effective 12/04/2020, 3:00 pm eastern
Research Committee(s)
Gastrointestinal Cancer
Activated
12-04-2020
ClinicalTrials.gov Registry Number
NCT04548752
Open
Phase
II
SWOG Clinical Trial Number
CTSU/AALL1821
Open
Phase
III
SWOG Clinical Trial Number
CTSU/EA2176

A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

Research Committee(s)
Gastrointestinal Cancer
Activated
10-15-2020
ClinicalTrials.gov Registry Number
NCT04444921
Open
Phase
II
Accrual
4%
SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases

Status Notes
Activation, Effective 9/23/2020, 2:00 pm eastern
Research Committee(s)
Melanoma
Activated
09-23-2020
ClinicalTrials.gov Registry Number
NCT04511013
Open
Phase
I-II
Accrual
6%
SWOG Clinical Trial Number
S1905

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

Status Notes
This study is open to accrual effective August 17, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Leukemia
Lymphoma
Activated
08-17-2020
ClinicalTrials.gov Registry Number
NCT#04315324
Open
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Research Committee(s)
Lung Cancer
Activated
08-17-2020
ClinicalTrials.gov Registry Number
NCT04402788
Open
SWOG Clinical Trial Number
CTSU/A021806

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Status Notes
This study is active in SWOG as of July 1, 2020.
Research Committee(s)
Gastrointestinal Cancer
Activated
07-01-2020
Open
SWOG Clinical Trial Number
CTSU/A081801

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Research Committee(s)
Lung Cancer
Activated
06-23-2020
ClinicalTrials.gov Registry Number
NCT04267848
Open
Phase
Accrual
6%
SWOG Clinical Trial Number
S1933

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

Status Notes
This study is open to accrual effective June 15, 2020 at 12:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
NCT04310020
Open
Phase
II
Accrual
24%
SWOG Clinical Trial Number
S1929

Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)

Status Notes
S1929 will open to accrual June 15, 2020, effective 12:00 pm PST.
Research Committee(s)
Lung Cancer
Activated
06-15-2020
ClinicalTrials.gov Registry Number
04334941
Open
SWOG Clinical Trial Number
CTSU/A151804

ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS

Status Notes
This study is active in SWOG as of June 15, 2020.
Research Committee(s)
Immunomolecular Therapeutics
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Leukemia
Lung Cancer
Lymphoma
Melanoma
Myeloma
Early Therapeutics & Rare Cancers
Activated
06-15-2020